Mylan, Others To Pay $124M Over Medicaid Rebates

Law360, New York (October 19, 2009, 5:56 PM EDT) -- Mylan Inc. and several other pharmaceutical companies will pay a combined sum of $124 million to settle allegations that they bilked state Medicaid programs of millions of dollars by improperly classifying certain drugs for rebate purposes.

The U.S. Department of Justice on Monday announced the settlement, which resolves pending litigation in the U.S. District Court for the District of New Hampshire. The case, initially filed as a whistleblower suit by a Florida-based pharmacy, accused Mylan, AstraZeneca Pharmaceuticals, AstraZeneca Pharmaceuticals LP and Ortho-McNeil Pharmaceutical of violating the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.